HANGZHOU, China, March 9 /PRNewswire-FirstCall/ -- BAS Consulting, Inc. , one of mainland China's leading pharmaceutical companies, today announced that the Company has changed its name to "Aida Pharmaceuticals, Inc." The action was approved by the Company's board of directors and stockholders. The Company will continue to trade on the OTC Bulletin Board under the symbol 'AIDA'.
Jin Biao, Aida Pharmaceuticals' Chairman, noted, "The new name more accurately reflects our business focus and position within the broader Chinese pharmaceuticals market. This move is more than a name change, in that it also reflects a refinement in our position and focus."
Mr. Jin continued, "Aida Pharmaceuticals' focus is executing on our core competencies to deliver best of breed antibiotics, cardiovascular and cancer drugs. Combined with our industry-leading management team and strategic partnerships across China, we feel that Aida Pharmaceuticals will be a benchmark company at the forefront of China's drug industry."
About Aida Pharmaceuticals
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP and ISO9002 certified for global quality assurance and ISO14000 certified for ecologically-friendly practices.
Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Gary Geraci (617) 723-2373 gary@equityperfgp.com
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov.
Aida Pharmaceuticals, Inc.CONTACT: Gary Geraci of Equity Performance Group for Aida Pharmaceuticals,Inc., +1-617-723-2373, gary@equityperfgp.com
